Hot Investor Mandate 10: New VC Firm Focuses Exclusively in Life Science Companies that Address Neurological and Psychiatric Disease Therapeutics

4 Jan

A newly established venture capital firm is dedicated to funding private, early stage, pre-clinical and clinical neuroscience therapeutics and technologies for neurological and psychiatric diseases and disorders. The firm invests in Seed and Series A rounds, typically allocating $1-10 million USD for each deal. The firm looks for deals globally and plans to make 8-10 investments in the upcoming year. The firm is willing to lead rounds or co-invest as long as the investment falls within their investment criteria.

The firm is interested in devices, digital health, therapeutics, and diagnostics companies that focus on treating those with psychiatric and neurological diseases. The firm prefers technologies and therapeutics that are disease modifying and/or gain significant traction in disease symptom reduction. Technologies that improve quality of life or treatment delivery in neurological and psychiatric patient populations will also be considered. The firm is primarily interested in therapeutics and technologies that are pre-clinical or in development.

The firm sometimes prefers to take a board seat in companies in which they invest and prefers management teams that have a strong technical background within the clinical neuroscience area of focus.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: